William Blair’s Dmitry Netis highlights key insights after meeting with FNSR CEO Kurt Adzema yesterday at the analyst’s Silicon Valley investor bus tour.
Even with slightly lower expectations, Raymond James’ John Freeman spotlights 66% upside potential for OAS shares.
Maxim’s Jason Kolbert is keeping his focus peeled to the Omeros pipeline, even though he welcomes the FDA victory for Omidria.
The total addressable market opportunity for SHOP shines brightly ahead as Raymond James’ Brian Peterson makes a bullish case for the Canadian e-commerce platform.
How long will bull run last for GPU makers?
Why patient deaths don’t necessarily scuttle Global Blood’s chances for voxelotor’s clinical success.
ASH data offers insight into Gilead Sciences’ lymphoma drug Yescarta; Maxim’s Jason McCarth weighs in.
Even with lower expectations., Maxim’s Michael Diana nonetheless highlights 104% in upside potential for LC shares.
Loup Ventures’ Gene Munster likens the Bitcoin revolution to that of the dot-com bubble collapse- but technological transformation of the way humans live in the world today.
Maxim’s Jason Kolbert is betting on SPHS to “unlock” share value with prostate cancer asset topsalysin.